Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management.
Edward K AvilaSteven TobochnikSara K InatiJohan A F KoekkoekGuy M McKhannJames J RivielloRoberta RudàDavid SchiffWilliam O TatumJessica W TemplerMichael WellerPatrick Y WenPublished in: Neuro-oncology (2023)
Tumor-related epilepsy (TRE) is a frequent and major consequence of brain tumors. Management of TRE is required throughout the course of disease and a deep understanding of diagnosis and treatment is key to improving quality of life. Gross total resection is favored from both an oncologic and epilepsy perspective. Shared mechanisms of tumor growth and epilepsy exist, and emerging data will provide better targeted therapy options. Initial treatment with antiseizure medications (ASM) in conjunction with surgery and/or chemoradiotherapy is typical. The first choice of ASM is critical to optimize seizure control and tolerability considering the effects of the tumor itself. These agents carry a potential for drug-drug interactions and therefore knowledge of mechanisms of action and interactions is needed. A review of adverse effects is necessary to guide ASM adjustments and decision-making. This review highlights the essential aspects of diagnosis and treatment of TRE with ASMs, surgery, chemotherapy, and radiotherapy while indicating areas of uncertainty. Future studies should consider the use of a standardized method of seizure tracking and incorporating seizure outcomes as a primary endpoint of tumor treatment trials.
Keyphrases
- temporal lobe epilepsy
- minimally invasive
- decision making
- locally advanced
- coronary artery bypass
- palliative care
- healthcare
- early stage
- radiation therapy
- randomized controlled trial
- squamous cell carcinoma
- adipose tissue
- type diabetes
- open label
- radiation induced
- coronary artery disease
- climate change
- machine learning
- percutaneous coronary intervention
- clinical practice
- radical prostatectomy
- adverse drug
- replacement therapy
- study protocol
- double blind
- data analysis